After approximately 8 years, postmenopausal women withhormone-sensitive breast cancer who received (Arimidex),generically known as anastrazole, had a lower risk of recurrencethan women taking tamoxifen, investigators reported at the annualmeeting of the San Antonio Breast Cancer Symposium.
More...